| abstract |
ABSTRACT Disclosed herein are alpha 2B receptor agonists and their use in the treatment of a variety of conditions and/or diseases including pain, neuritis, rheumatoid arthritis, autoimmune uveitis, dry eye disease, Guillan-Barre syndrome, inflammation, diabetes graft vs host disease, sjogren's syndrome, atopic dermatitis, psoriasis, inflammatory bowel disease, irritable bowel syndrome, asthma and systemic autoimmune disorder, wherein the alpha-2B receptor agonist is an imidazoline or an imidazole. Date recue / Date received 2021-11-26 |